Related Experiment Video
Updated: Dec 9, 2025

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Targeting Epigenetics in Lung Cancer
1Department of Medicine, Division of Hematology and Oncology, University of North Carolina, Chapel Hill, North Carolina 27514, USA.
Abstract:
The epigenetic landscape, which in part includes DNA methylation, chromatin organization, histone modifications, and noncoding RNA regulation, greatly contributes to the heterogeneity that makes developing effective therapies for lung cancer challenging. This review will provide an overview of the epigenetic alterations that have been implicated in all aspects of cancer pathogenesis and progression as well as summarize clinical applications for targeting epigenetics in the treatment of lung cancer.
Insights
Lung cancer
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Epigenetic alterations, including DNA methylation and histone modifications, contribute to lung cancer's complex nature.
- These epigenetic changes drive tumor heterogeneity, posing challenges for effective treatment development.
Purpose of the Study:
- To review epigenetic alterations in lung cancer pathogenesis and progression.
- To summarize clinical applications of targeting epigenetics in lung cancer treatment.
Main Methods:
- Literature review of epigenetic mechanisms in lung cancer.
- Analysis of current clinical strategies targeting epigenetic modifications.
Main Results:
- Epigenetic landscape significantly impacts lung cancer development and progression.
- Targeting epigenetic modifications shows promise for novel lung cancer therapies.
Conclusions:
- Understanding the epigenetic landscape is crucial for overcoming lung cancer heterogeneity.
- Epigenetic therapies offer a potential avenue for improving lung cancer treatment outcomes.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Targeted Cancer Therapies
There are several types of targeted therapies against...

